Literature DB >> 21177675

Spread of Escherichia coli O25b:H4-B2-ST131 producing CTX-M-15 and SHV-12 with high virulence gene content in Barcelona (Spain).

Alicia Coelho1, Azucena Mora, Rosalia Mamani, Cecilia López, Juan José González-López, María Nieves Larrosa, J Natalia Quintero-Zarate, Ghizlane Dahbi, Alexandra Herrera, Jesús E Blanco, Miguel Blanco, María Pilar Alonso, Guillem Prats, Jorge Blanco.   

Abstract

OBJECTIVES: The present study was carried out to evaluate the current prevalence of the clonal group O25b:H4-B2-ST131 among extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (ESBLEC) collected in the Hospital Vall d'Hebron in Barcelona (Spain) with regard to other clonal groups and to characterize their genetic background.
METHODS: Ninety-four consecutive non-duplicate ESBLEC isolates collected from May to December 2008 were studied. ESBL enzymes, phylogenetic groups, serotypes, virulence genes, sequence types (STs) and PFGE profiles were determined. Results The most prevalent ESBLs were CTX-M-14 (47%), CTX-M-15 (26%) and SHV-12 (19%). Thirty (32%) of the 94 ESBLEC isolates belonged to the clonal group O25b:H4-B2-ST131 of which 19 (63%) carried the bla(CTX-M-15) gene and eight (27%) the bla(SHV-12) gene. Moreover, five additional clonal groups (O15/O25a:H1/HNM-D-ST393, O78:HNM-A-ST369, ONT:H21,42/HNM-B1-ST101, O9:H4-A-ST410 and O8:H19-B1-ST162) were detected among 16 isolates producing CTX-M-14 and SHV-12. The 30 ST131 isolates exhibited a significantly higher virulence score (mean number of virulence genes 9.60 versus 5.84) compared with the 64 non-ST131 isolates. In particular, the SHV-12-producing ST131 isolates showed the highest virulence score (range 8-13, mean score 11.75).
RESULTS: also revealed that the 30 ST131 isolates were distributed in five different groups according to their virulence, XbaI macrorestriction and resistance patterns.
CONCLUSIONS: We report for the first time the clonal spread of SHV-12-producing O25b:H4-B2-ST131 isolates characterized by high virulence gene content. Moreover, we describe the distribution of the ST131 isolates within different virulence groups.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21177675     DOI: 10.1093/jac/dkq491

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  31 in total

Review 1.  Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection.

Authors:  Thomas J Hannan; Makrina Totsika; Kylie J Mansfield; Kate H Moore; Mark A Schembri; Scott J Hultgren
Journal:  FEMS Microbiol Rev       Date:  2012-05       Impact factor: 16.408

Review 2.  Escherichia coli ST131, an intriguing clonal group.

Authors:  Marie-Hélène Nicolas-Chanoine; Xavier Bertrand; Jean-Yves Madec
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

3.  Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages.

Authors:  Amee R Manges; Hyun Min Geum; Alice Guo; Thaddeus J Edens; Chad D Fibke; Johann D D Pitout
Journal:  Clin Microbiol Rev       Date:  2019-06-12       Impact factor: 26.132

4.  Characterization of a P1-like bacteriophage carrying an SHV-2 extended-spectrum β-lactamase from an Escherichia coli strain.

Authors:  Typhaine Billard-Pomares; Stéphanie Fouteau; Marie Elise Jacquet; David Roche; Valérie Barbe; Miguel Castellanos; Jean Yves Bouet; Stéphane Cruveiller; Claudine Médigue; Jorge Blanco; Olivier Clermont; Erick Denamur; Catherine Branger
Journal:  Antimicrob Agents Chemother       Date:  2014-08-18       Impact factor: 5.191

5.  Contribution of IncFII and broad-host IncA/C and IncN plasmids to the local expansion and diversification of phylogroup B2 Escherichia coli ST131 clones carrying blaCTX-M-15 and qnrS1 genes.

Authors:  Ângela Novais; Diana Viana; Fernando Baquero; Javier Martínez-Botas; Rafael Cantón; Teresa M Coque
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

6.  Inhibitor-resistant TEM- and OXA-1-producing Escherichia coli isolates resistant to amoxicillin-clavulanate are more clonal and possess lower virulence gene content than susceptible clinical isolates.

Authors:  Jesús Oteo; Juan José González-López; Adriana Ortega; J Natalia Quintero-Zárate; Germán Bou; Emilia Cercenado; María Carmen Conejo; Luis Martínez-Martínez; Ferran Navarro; Antonio Oliver; Rosa M Bartolomé; José Campos
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

7.  First Report of Prevalence of CTX-M-15-Producing Escherichia coli O25b/ST131 from Iran.

Authors:  Mohammad Hasan Namaei; Masoud Yousefi; Masoud Ziaee; Alireza Salehabadi; Malaknaz Ghannadkafi; Elham Amini; Parvin Askari
Journal:  Microb Drug Resist       Date:  2017-02-16       Impact factor: 3.431

8.  Prevalence and characteristics of the epidemic multiresistant Escherichia coli ST131 clonal group among extended-spectrum beta-lactamase-producing E. coli isolates in Copenhagen, Denmark.

Authors:  Bente Olesen; Dennis S Hansen; Frida Nilsson; Jakob Frimodt-Møller; Rikke Fleron Leihof; Carsten Struve; Flemming Scheutz; Brian Johnston; Karen A Krogfelt; James R Johnson
Journal:  J Clin Microbiol       Date:  2013-04-03       Impact factor: 5.948

9.  Four main virotypes among extended-spectrum-β-lactamase-producing isolates of Escherichia coli O25b:H4-B2-ST131: bacterial, epidemiological, and clinical characteristics.

Authors:  Jorge Blanco; Azucena Mora; Rosalia Mamani; Cecilia López; Miguel Blanco; Ghizlane Dahbi; Alexandra Herrera; Juan Marzoa; Val Fernández; Fernando de la Cruz; Luis Martínez-Martínez; María Pilar Alonso; Marie-Hélène Nicolas-Chanoine; James R Johnson; Brian Johnston; Lorena López-Cerero; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  J Clin Microbiol       Date:  2013-08-07       Impact factor: 5.948

10.  Clonal structure, extended-spectrum β-lactamases, and acquired AmpC-type cephalosporinases of Escherichia coli populations colonizing patients in rehabilitation centers in four countries.

Authors:  R Izdebski; A Baraniak; J Fiett; A Adler; M Kazma; J Salomon; C Lawrence; A Rossini; A Salvia; J Vidal Samso; J Fierro; M Paul; Y Lerman; S Malhotra-Kumar; C Lammens; H Goossens; W Hryniewicz; C Brun-Buisson; Y Carmeli; M Gniadkowski
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.